Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lorlatinib in ALK-Positive NSCLC Post-2nd Gen TKI
NCT04362072Phase 4Completed
- Sponsor
- Pfizer
- Start
- Sep 2020
- Primary completion
- May 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 7
01
Overview
A Phase 4 trial of lorlatinib in non-small cell lung cancer (NSCLC), sponsored by Pfizer. Started Sep 2020; status: completed.
02
Drugs
lorlatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04362072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04362072.